Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2017 |
| gptkbp:ATCCode |
L01XC31
|
| gptkbp:brand |
gptkb:Bavencio
|
| gptkbp:CASNumber |
1537032-82-8
|
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:EMD_Serono |
| gptkbp:drugClass |
antineoplastic agent
|
| https://www.w3.org/2000/01/rdf-schema#label |
avelumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:CD274
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:PubChem_CID |
gptkb:DB12010
gptkb:CHEMBL3989989 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash elevated liver enzymes infusion-related reaction |
| gptkbp:target |
PD-L1
|
| gptkbp:treatment |
gptkb:urothelial_carcinoma
Merkel cell carcinoma |
| gptkbp:UNII |
8D8S983P7A
|
| gptkbp:usedFor |
immunotherapy
|
| gptkbp:bfsParent |
gptkb:Bavencio
|
| gptkbp:bfsLayer |
6
|